SAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ('Biomea” or 'Biomea Fusion” or 'the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that three icovamenib abstracts have been selected for late-breaking poster presentations at the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5-8, 2026 in New Orleans. The presentations include data from icovamenib, the Company’s investigational oral menin inhibitor, across both type 1 and type 2 diabetes, highlighting its potential to improve beta cell function and support metabolic health.